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Case Report
Carbamazepine-responsive paroxysmal nausea and
vomiting in a patient with meningeal carcinomatosis
Imke Strohscheer Section of Palliative Care, Medical University, Graz and Gian Domenico Borasio
Interdisciplinary Center for Palliative Medicine, Ludwig-Maximilians-University, Munich
In neurology, paroxysmal syndromes are well-known, eg, as manifestations of multiple
sclerosis. We report a patient with meningeal carcinomatosis, who presented with therapy-
refractory nausea and vomiting. The clinical suspicion of a paroxysmal syndrome prompted
a trial of carbamazepine, which resulted in complete cessation of the symptoms. In cancer
patients with central nervous system (CNS) involvement and therapy-refractory symptoms
with sudden onset, carbamazepine treatment should be considered. Palliative Medicine
2006; 20: 549550
Introduction
Therapy-refractory nausea and vomiting may result in
unacceptable suffering in patients with advanced cancer.
We report an unusual case of paroxysmal nausea and
vomiting responding to anti-convulsant treatment in a
patient with breast cancer. Paroxysmal syndromes are
well-known in neurology, eg, as manifestations of multi-
ple sclerosis. These syndromes present as sudden, short
bouts of a specific symptom (eg, pain, vertigo), usually
triggered by movement or external stimuli. The best
known example is trigeminal neuralgia.1 The literature
reports a few cases of paroxysmal nausea and
vomiting.24 To our knowledge, this is the first reported
case of a paroxysmal syndrome in a patient with
meningeal carcinomatosis.
Case history
A 39-year-old patient with metastatic breast cancer
presented with nausea and vomiting, headache, photo-
phobia and painful neck stiffness. A NMR of the
brain showed diffuse dural enhancements and plaques
(Figure 1). A spinal tap revealed malignant cells and
increased protein levels. The diagnosis of meningeal
carcinomatosis was made and intrathecal chemotherapy
was started.
Pain medication controlled the headache, but the
patient still suffered from sudden, visually and move-
ment-induced bouts of nausea and vomiting, which
caused her to lie in bed with closed eyes for most of the
time. These episodes were induced by almost every
movement of the patient. Treatment with metoclopra-
mide, 5-HT3-receptor-antagonists, dexamethasone and
levopromazine failed completely. The diagnosis of a
postural vertigo was excluded. The clinical suspicion of
a paroxysmal syndrome prompted a trial of carbamaze-
pine. Nausea and vomiting stopped immediately after a
first dosage of 100 mg. Interruption of medication
resulted in symptom recurrence on the next day. An
electroencephalogram (EEG) showed intermittent parox-
ysmal excitations. We re-started the medication with
carbamazepine 400 mg/day. This allowed the patient to
leave the bed and eat without nausea and vomiting.
Despite intrathecal chemotherapy, the patient’s condition
worsened and death ensued three weeks later, without
recurrence of the paroxysmal syndrome.
Discussion
We report an unusual, well-treatable clinical manifesta-
tion of meningeal carcinomatosis  paroxysmal nausea
and vomiting. The level of suffering was high, because
the patient had to lie immobile and close her eyes to
suppress the symptoms.
Nausea and vomiting are associated with a chemor-
eceptor trigger zone in the area postrema and a vomiting
centre, both located in the medulla oblongata. Common
antiemetics, including serotonin antagonists, are usually
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able to control nausea and vomiting in incurable cancer
patients, but did not show any effect in our patient. The
dramatic effect of the first application of carbamazepine,
the recurrence of the symptoms after treatment interrup-
tion and the reproducible effect after re-administration of
the drug confirmed the clinical diagnosis of a paroxysmal
syndrome.
In central demyelinating disorders, paroxysmal
syndromes are thought to be due to ephaptic (ie,
non-synaptic) transmission of discharges between neigh-
bouring axons within areas of demyelination. Brainstem-
related paroxysms may present as paroxysmal dysarthria,
ataxia, diplopia, tonic seizures, akinesia, sensory distur-
bances, or pains.4 Visually-induced paroxysmal vomiting
has been reported in multiple sclerosis.2 Paroxysmal
vomiting has also been described as a manifestation of
temporal lobe epilepsy.5 The exact pathophysiological
mechanism leading to the paroxysmal syndrome in our
patient is unclear, but was likely related to the meningeal
carcinomatosis, which possibly caused local demyelina-
tion in the brainstem.
Carbamazepine is the drug of choice to suppress
paroxysms and the response is usually dramatic.4 Given
the high frequency of central nervous system (CNS)
involvement in tumour patients, currently, paroxysmal
symptoms may be under-diagnosed. In this group of
patients, therapy-refractory symptoms with sudden
onset (pain, vomiting, vertigo and other unclear neuro-
logical symptoms) should prompt a treatment trial with
carbamazepine.
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